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S U M M A R Y
Antimicrobial resistance is closely linked to antimicrobial use and is a growing concern worldwide.
Antimicrobial resistance increases healthcare costs substantially in many countries, including
Lebanon. National data from Lebanon have, in the most part, been limited to a few academic
hospitals. The Lebanese Society of Infectious Diseases conducted a retrospective study to better
describe the antimicrobial susceptibility patterns of bacterial isolates in Lebanon. Data were based on
records retrieved from the bacteriology laboratories of 16 different Lebanese hospitals between
January 2011 and December 2013. The susceptibility results of a total 20 684 Gram-positive and
55 594 Gram-negative bacteria were analyzed. The prevalence rate of methicillin-resistant
Staphylococcus aureus was 27.6% and of vancomycin-resistant Enterococcus spp was 1%. Streptococcus
pneumoniae had susceptibilities of 46% to oxacillin, 63% to erythromycin, and 98% to levoﬂoxacin.
Streptococcus pyogenes had susceptibilities of 94% to erythromycin and 95% to clindamycin. The mean
ampicillin susceptibility of Haemophilus inﬂuenzae, Salmonella spp, and Shigella spp isolates was 79%,
81.3%, and 62.2%, respectively. The extended-spectrum beta-lactamase production rate for
Escherichia coli was 32.3% and for Klebsiella spp was 29.2%. Acinetobacter spp showed high resistance
to most antimicrobials, with low resistance to colistin (17.1%). Pseudomonas spp susceptibilities to
piperacillin–tazobactam and imipenem were lower than 80% (79.7% and 72.8%, respectively). This
study provides population-speciﬁc data that are valuable in guiding antimicrobial use in Lebanon and
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Antimicrobial resistance is a public health concern worldwide,
particularly in developing nations, and is associated with many
socio-cultural factors. Over the last 70 years, bacteria have become
resistant to nearly all clinically relevant antibiotic agents. The
United States Centers for Disease Control and Prevention (CDC)
estimates that at least two million Americans become infected
with antibiotic-resistant bacteria each year, with at least
23 000 people dying yearly as a direct result of these infections.1
Countries in the Arabian Gulf including Saudi Arabia, the United
Arab Emirates, Kuwait, Qatar, Oman, and Bahrain share a high
prevalence of infections due to extended-spectrum beta-lactamase
(ESBL)- and carbapenemase-producing Gram-negative bacilli.2
The single most important factor leading to antimicrobial
resistance globally is the overuse/misuse of antimicrobials.1 This is
mainly due to incorrect diagnosis, the irrational use of anti-
microbials, and irregular consumption, the latter due either to an
incorrect prescription or to poor compliance. Up to 50% of all
antimicrobials prescribed for patients are not needed or are not
optimal as prescribed.3 A core action to ﬁght the spread of
antimicrobial resistance is their improved use. The lack of
implementation of adequate infection control measures has
complicated this goal, necessitating urgent intervention.
Infections caused by antibiotic-resistant organisms continue to
add considerable and avoidable costs to the already overburdened
Lebanese healthcare system. The infections lead to complications
that require additional therapeutic interventions, including in-
dwelling catheters, sophisticated life support, intravenous ﬂuid
therapy, and prosthetic devices. They can also extend the hospital
stay and the use of broad-spectrum antimicrobials appreciably,
which in turn can increase the prevalence rate of multidrug-
resistant pathogens.
The pattern of antimicrobial resistance changes with time and
varies from country to country and also between hospitals within
the same country. Therefore, data on the prevailing regional Figure 2. Distribution of hospital beds.
neighbouring countries and will help in the establishment of a surveillance system for antimicrobial
resistance following the implementation of a nationwide standardization of laboratory methods and
data entry.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Figure 1. Geographic distribution of participating hospitals.resistance and trends of clinically important bacterial isolates are
helpful for physicians making decisions concerning the appropri-
ate empirical treatment of various infections.
In Lebanon, the resistance trends of bacterial isolates have
been reported in a few hospitals for several years. However,
similar information does not exist at the national level. The
Lebanese Society of Infectious Diseases (LSID) study group
conducted the present study to better describe the national
antimicrobial resistance patterns among clinically relevant
pathogens. The LSID also intends to implement a database into
which laboratories using standardized techniques can enter their
data on a regular basis. This will allow the establishment of a
surveillance system in Lebanon, which will help in combating
antimicrobial resistance.
2. Methods
This retrospective study was based on the records of
antimicrobial susceptibility tests performed on bacterial isolates
in the bacteriology laboratories of 16 different tertiary care centres,
representing 40.7% of all hospital beds in Lebanon. Hospitals and
hospital bed distribution data are presented in Figures 1 and 2,respectively. The only governorate that was not represented in this
study was Bekaa.
The study team collected data related to tests performed
between January 2011 and December 2013. The data collected
were primarily qualitative (resistant, intermediate, or susceptible).
Data were then tabulated in Excel spreadsheets. Most of the
laboratories generated their data using WHONET software. In an
attempt to standardize the selection criteria for bacterial isolates
and avoid the duplication of isolates, laboratories not using
WHONET software included only the ﬁrst isolate from each patient
with different antibiotic susceptibility proﬁles (criteria for selec-
tion set for WHONET). Six hospitals provided data for the year
2011, 12 provided data for 2012, and 13 provided data for
2013. Clinical specimens included urine, sputum, deep tracheal
aspirates, blood, body ﬂuids, central line tips, and others. The
characteristics of the participating hospitals, as well as the testing
methods and guidelines followed at each institution, are presented
in Table 1. Non-automated tests with oxacillin and cefoxitin4 and a
double-disc synergy test5 were used for the detection of
methicillin-resistant Staphylococcus aureus (MRSA) and ESBL-
producing bacteria, respectively.
Table 1
Demographics and testing guidelines related to the participating hospitals
Hospital Region Type Beds Methoda Guidelines
Abou Jaoude Mount Lebanon Community 110 DD CLSI
AUBMC Beirut University 350 DD CLSI
BMC Mount Lebanon University 110 DD SFM
CHN North Lebanon University 200 DD CLSI
Hammoud South Lebanon University 500 Automated CLSI
HDF Beirut University 450 Automated EUCAST
UMCRH Beirut University 90 DD CLSI
Makassed Beirut University 200 DD CLSI
Mazloum North Lebanon Community 180 DD
+ automated
CLSI
+ EUCAST
MEIH Mount Lebanon University 200 DD SFM
MLH Mount Lebanon University 240 Automated CLSI
NDS Mount Lebanon University 250 Automated CLSI
NINI North Lebanon Community 120 DD EUCAST
RHUH Beirut University 350 Automated CLSI
SCH Mount Lebanon University 200 DD EUCAST
SGH Beirut University 400 DD CLSI
AUBMC, American University of Beirut Medical Center; BMC, Bellevue Medical
Center; CHN, Centre Hospitalier du Nord; HDF, Hotel Dieu de France; UMCRH,
University Medical Center Rizk Hospital; MEIH, Middle East Institute of Health;
MLH, Mount Lebanon Hospital; NDS, Notre Dame des Secours; NINI; RHUH, Raﬁk
Hariri University Hospital; SCH, Sacre´ Coeur Hospital; SGH, Saint Georges Hospital;
DD, disc diffusion; CLSI, Clinical and Laboratory Standards Institute; SFM, Societe´
Franc¸aise de Microbiologie; EUCAST, European Committee on Antimicrobial
Susceptibility Testing.
a Automated microbial identiﬁcation system: Vitek, BD Phoenix.
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Microsoft Excel spreadsheets, veriﬁed, and analyzed using Micro-
soft Excel 2007. The rates of susceptibility to individual
antimicrobials were calculated for every bacterial isolate by
hospital, year of isolation, and region. The mean percentages of
the susceptibility of each isolate to all tested antimicrobials were
calculated. Yearly and regional comparisons were performed using
the Chi-square test after checking the applicability conditions. A p-
value of < 0.05 was considered signiﬁcant. When comparing
results from the three different years, p < 0.05 was considered
statistically signiﬁcant if at least one value was different from theTable 2
Gram-positive and Gram-negative isolates
Gram-positive isolates Total number
collected
Proportion
(Gram-positive)
Coagulase-negative Staphylococcus 8194 39.6%
Staphylococcus aureus 4890 23.6%
Enterococcus spp 4145 20%
Streptococcus agalactiae 1386 6.7%
Streptococcus pyogenes 1059 5.1%
Streptococcus pneumoniae 648 3.1%
Streptococcus viridans group 362 1.8%
Total Gram-positive 20 684 100%
Gram-negative isolates Total number
collected
Proportion
(Gram-negative)
Escherichia coli 30 411 54.7%
Pseudomonas aeruginosa 7897 14.2%
Klebsiella spp 7883 14.2%
Acinetobacter spp 3409 6.1%
Enterobacter spp 2207 4.0%
Salmonella spp 877 1.6%
Citrobacter spp 738 1.3%
Morganella morganii 675 1.2%
Haemophilus inﬂuenzae 552 1.0%
Serratia spp 480 0.9%
Shigella spp 164 0.3%
Proteus spp 162 0.3%
Moraxella catarrhalis 139 0.2%
Total Gram-negative 55 594 100%
Total Gram-positive and
Gram-negative isolates
76 278others. In the case where the Chi-square test could not be applied
because of an expected count in a cell of less than 5, the two-sided
Fisher’s exact test was used.
3. Results
The susceptibility results of 20 684 Gram-positive and
55 594 Gram-negative bacteria collected from 16 different hospi-
tals in Lebanon (3950 beds) between January 2011 and December
2013 were analyzed. The isolates are summarized in Table 2. The
most common Gram-negative species isolated was Escherichia coli,
followed by Pseudomonas aeruginosa and Klebsiella spp.
A total 4890 S. aureus isolates were collected in the 16 hospitals.
The prevalence of MRSA extrapolated based on resistance to
oxacillin and cefoxitin was 27.6%. The susceptibility of S. aureus
isolates to erythromycin and clindamycin was stable (mean 76%
and 83.2%, respectively). Mean susceptibilities to the most relevant
antimicrobials are presented in Table 3. The vancomycin-non-
susceptible isolates from 2012 were not independently conﬁrmed;
the data were thus considered as only presumptive, requiring
further investigation. This ﬁnding suggests the need for greater
vigilance in the process of detecting and reporting this important
type of resistance.
The mean susceptibility results for the 648 isolates of
Streptococcus pneumoniae and 986 isolates of Streptococcus
pyogenes are presented in Table 3. S. pneumoniae isolates displayed
low susceptibility to oxacillin (46.2%). A statistically signiﬁcant
decreasing trend in erythromycin susceptibility was noted, from
69.4% in 2011 to 58.7% in 2013. High susceptibilities were evident
to levoﬂoxacin (98%) and ceftriaxone (95%).
The susceptibility of Enterococcus spp to ampicillin was 84.4%,
with a decreasing trend, from 91.1% in 2011 to 81.6% in
2013. Vancomycin-resistant enterococci (VRE) were reported from
six centres, with a rate of 1% (Table 3). Some hospitals reported
Enterococcus faecalis and Enterococcus faecium separately, while
others made no distinction between Enterococcus species. The data
reported here are for all Enterococcus species.
The mean susceptibilities of Haemophilus inﬂuenzae did not
differ from 2011 to 2013. The mean susceptibility to ampicillin was
79%. The susceptibility to both levoﬂoxacin and ciproﬂoxacin was a
mean of 93% (Table 4).
Salmonella spp showed a mean susceptibility of 81.3% to
ampicillin and 95% to ciproﬂoxacin. The susceptibility to trimeth-
oprim–sulfamethoxazole decreased in 2013 to about 88%, but this
decrease was not statistically signiﬁcant. Susceptibility to ceftri-
axone remained high at 97.3% (Table 4). Nalidixic acid susceptibil-
ity, which was reported from one centre only, was 75% (n = 4) for
Salmonella Typhi and 11% for non-Typhi Salmonella (n = 28).
Shigella spp showed 62.2% susceptibility to ampicillin, 99% to
ciproﬂoxacin, and 28% to trimethoprim–sulfamethoxazole. Sus-
ceptibility to ceftriaxone remained high at 89.1% (Table 4).
The mean susceptibilities of E. coli isolates are presented in
Table 5. The average ESBL production was found to be 32.3% during
the study period. In the years 2011, 2012, and 2013, the ESBL
production rates were 32.0%, 30.8%, and 33.6%, respectively. E. coli
showed the least resistance to imipenem (mean resistance of 0.7%),
and this was stable over the 3-year study period. Resistance to
nitrofurantoin and tigecycline was low (4% and 1.8%, respectively).
Susceptibility to most cephalosporins showed a statistically
signiﬁcant decreasing trend. Susceptibility to ciproﬂoxacin also
decreased from 2011 to 2013, with mean values of 57.4% in
2011 and 52.0% in 2013. Among the aminoglycosides, E. coli was
more susceptible to amikacin than gentamicin, with mean
susceptibilities of 97.2% and 71.7%, respectively, and these were
stable during the study period (Table 5).
Table 3
Susceptibility rates of Gram-positive organisms obtained from 16 Lebanese hospitals
Percentage susceptibility to the antimicrobial agents (number of isolates)
Staphylococcus aureus Streptococcus pneumoniae
2011 (790) 2012 (1717) 2013 (2383) All years
(4890)
p-Value 2011 (102) 2012 (230) 2013 (316) All years
(648)
p-Value
Oxacillin 76.4 (790) 72.1 (1717) 72.9 (2245) 73.3 0.066 50.5 (61) 44.3 (201) 46.7 (239) 46.2 0.205
Ceftriaxone 94.5 (94) 92.4 (92) 97.5 (81) 94.7 <0.05a
Tigecycline 100 (12) 98.8 (236) 100 (244) 99.4 <0.05a,b
TMP–SMX 91.1 (595) 91.6 (1679) 90.5 (2330) 90.9 0.475 52.9 (17) 52.2 (160) 53.3 (119) 52.6 0.654
Levoﬂoxacin 88.3 (300) 83.0 (1213) 84.0 (784) 84 <0.05a 98.5 (70) 96.6 (210) 99.6 (203) 98.1 <0.05b
Erythromycin 76.2 (790) 76.0 (1717) 75.9 (2383) 76 0.986 69.4 (102) 64.6 (230) 58.7 (212) 63.2 <0.05b
Clindamycin 85.8 (759) 81.5 (1535) 83.7 (2065) 83.2 <0.05a 82.0 (94) 73.0 (212) 76.4 (282) 76 0.183
Vancomycin 100 (790) 99.1 (1717) 100 (2383) 99.7 <0.05a,b
Streptococcus pyogenes Enterococcus spp
2011 (60) 2012 (459) 2013 (467) All years
(986)
p-Value 2011 (538) 2012 (1666) 2013 (1941) All years
(4145)
p-Value
Penicillin 100 (60) 100 (459) 100 (160) 100
Ampicillin 91.1 (518) 85.5 (1415) 81.6 (1914) 84.4 <0.05a,b
Tigecycline 100 (67) 99.0 (388) 100 (268) 99.4 <0.05a,b
Erythromycin 88.4 (60) 93.7 (459) 94.9 (467) 94 <0.05a
Clindamycin 83.3 (30) 95.4 (450) 96.1 (419) 95.3 <0.05a
Vancomycin 100 (538) 99.0 (1666) 98.8 (1941) 99 <0.05a
Teicoplanin 100 (538) 97.7 (1400) 98.8 (1941) 98.6 <0.05a,b
TMP–SMX, trimethoprim–sulfamethoxazole.
p-Value reports at least one signiﬁcant difference between any percentages.
a p-value <0.05 between 2011 and 2012.
b p-value <0.05 between 2012 and 2013.
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antimicrobials are presented in Table 5. In the years 2011, 2012,
and 2013, the ESBL production rates in Klebsiella were 30.2%,
28.1%, and 29.9%, respectively (mean 29.2%). Klebsiella spp showed
the highest susceptibility to imipenem (98%) and amikacin (95.7%),
followed by tigecycline (87%). A low resistance to carbapenems, a
relatively low susceptibility to trimethoprim–sulfamethoxazole,
and a statistically signiﬁcant decline in susceptibility to nitrofur-
antoin were noted.
Four hospitals reported the susceptibility to Acinetobacter
baumannii, while all of the others reported the susceptibility of
Acinetobacter spp. The mean susceptibilities of Acinetobacter spp are
presented in Table 6. Acinetobacter spp showed high resistance to
most of the antimicrobials and low resistance to colistin. The
susceptibility to colistin was 77.1% in 2012 and 95.6% in 2013, with
a mean of 82.9% (Table 6).
The mean susceptibilities of Pseudomonas spp are presented in
Table 6. Susceptibility to ceftazidime ranged between 78.4% and
83.3%. Susceptibilities to both aztreonam and imipenem were
lower than 80%, while ciproﬂoxacin was associated with suscepti-
bility ranging between 74.8% and 80.3%.
4. Discussion
The ﬁrst comprehensive report of the antimicrobial suscepti-
bility of bacterial isolates in Lebanon was published in 1994 fol-
lowing an investigation by Araj et al. on the susceptibility patterns
of clinical isolates at the American University of Beirut Medical
Center (AUBMC) from March 1992 through June 1993. The overall
antimicrobial resistance rates did not differ signiﬁcantly from
those reported in the Arabian Gulf countries and US medical
centres.6 The surveillance of bacterial susceptibility to antimicro-
bials was performed in selected, mainly academic hospitals in
Lebanon. Each hospital reported its own data separately. The
present study is the ﬁrst to compile data generated by different
hospitals representing most regions of the country.
S. aureus is a major pathogen in both the hospital environment
and the wider community. It causes a wide variety of infectionsthat are associated with considerable morbidity and signiﬁcant
mortality. The high prevalence of MRSA found in this study (27.6%)
may reﬂect healthcare-associated infections that are difﬁcult to
control. The transmission of MRSA may occur during bed-making,
changing of clothes, and sneezing, and may result from poor
hygiene practices.7,8 Many hospitals in Lebanon do not use contact
isolation for patients with MRSA, which could be a cause of this
high reported rate.
Among all resistant pathogens, MRSA is of particular concern
because of its importance in causing various clinical conditions.
MRSA prevalence differed among the hospitals, being low (<20%)
in some and exceeding 30% in others, suggesting possible
outbreaks in some of these centres.
Between 2003 and 2005, the ARMed (Antibiotic Resistance
Surveillance and Control in the Mediterranean Region) project
reported an MRSA rate of 39% among the susceptibility test results
of 5000 invasive isolates of S. aureus obtained from blood cultures
in 62 hospitals located in Algeria, Cyprus, Egypt, Jordan, Lebanon,
Malta, Morocco, Tunisia, and Turkey.9 Lebanon appears to have a
lower MRSA rate.
In the study conducted by Araj et al., there was a signiﬁcant
increase in the prevalence of MRSA from 3% in 1971 to 38% in
1999.6 However, rates at AUBMC have been around 20% in the last
decade. Vancomycin-intermediate S. aureus and vancomycin-
resistant S. aureus strains were not reported.10 The present
nationwide data collected from 16 hospitals over a period of
3 years indicate an MRSA rate of 27.6%.
Previously reported rates of penicillin resistance of S. pneumo-
niae isolates in Lebanon between 1990 and 1996 were 13% in
AUBMC and 12% in Makassed General Hospital.11,12 A study
conducted from 2000 to 2004 in a Beirut hospital reported that
only 40.6–50% of S. pneumoniae isolates were susceptible to
penicillin G, with a decreasing trend in the susceptibility to
clindamycin and erythromycin.13 The pattern of resistance of S.
pneumoniae was assessed again in 2011; 48% of isolated species
were susceptible to penicillin, 50% were intermediate, and 1.6%
were fully resistant to this antibiotic.14 Other data from Lebanon
and the region have indicated S. pneumoniae susceptibility rates of
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2005,15 with markedly higher rates of penicillin resistance (60–
72%) reported at AUBMC between 2000 and 2011.10
Penicillin resistance of S. pneumoniae has been correlated with
the nationwide use of penicillin.16 The Lebanese Inter-Hospital
Pneumococcal Surveillance Program was established to determine
the burden of invasive pneumococcal disease and the prevalent
serotypes. The ﬁrst nationwide data from the program published in
2012 indicated a penicillin resistance rate of 17.5% using the new
Clinical and Laboratory Standards Institute (CLSI) breakpoints.17
This is markedly less than the present resistance rate of 53.8%. The
discrepancy may be due to the use of the older, pre-2008 CLSI
breakpoint in most of the centres, or may be because of the use of
‘meningitis’ or ‘non-meningitis’ or ‘oral’ breakpoints. Information
on the breakpoint used by the microbiology laboratories was not
available. It is believed that the rate of susceptibility to penicillin is
closer to that reported by the Pneumococcal Surveillance Program.
On the other hand, the susceptibility of S. pneumoniae to
erythromycin was low (63%), possibly because of the overuse of
this class of antimicrobial in Lebanon, since all oral antimicrobials
are available over the counter. S. pneumoniae susceptibility to
levoﬂoxacin remained high (98%). S. pyogenes remained sensitive
to ampicillin during the study period. This ﬁnding is universal.
In an earlier study conducted at AUBMC, the rate of ampicillin
susceptibility of Enterococcus spp ranged from 95% to 84% and VRE
rates were low.10 In the present study, the rate of Enterococcus spp
susceptibility to ampicillin was similar at 84.4% and the VRE rate
was low (1%). The data reported here are for all Enterococcus
species, as not all hospitals made a distinction between the
Enterococcus species.
A prior evaluation of H. inﬂuenzae isolates at a Beirut hospital
revealed resistance to amoxicillin–clavulanate, ceftriaxone, cipro-
ﬂoxacin, and rifampicin, with more than 92% of isolates showing
susceptibility to cefuroxime, chloramphenicol, erythromycin, and
tetracycline.13 The high susceptibility of H. inﬂuenzae to the
aforementioned antimicrobials was found to have continued in the
present study (>92%).
Araj et al. reported high susceptibility of Salmonella and
Shigella in 2012.10 In the present study, Salmonella and Shigella
susceptibilities to ampicillin were 81% and 62%, respectively.
Susceptibilities to trimethoprim–sulfamethoxazole were lower, at
88% and 28%, respectively. High susceptibilities to ciproﬂoxacin
and ceftriaxone were reported during the 3 years of the study.
Resistance of Shigella spp to third-generation cephalosporins was
ﬁrst detected in Lebanon in 2005; this subsequently increased, and
ESBL-producing strains were revealed.18,19
In 2003, the rate of ESBL-producing E. coli was found to be 2.0%
in a large hospital in Beirut.20 Later studies chronicled increased
rates of ESBL-producing E. coli isolates from about 4% in 2000 to
about 30% in 2011.10,21 An investigation of the susceptibility
proﬁles of E. coli at one centre between 2000 and 2009 revealed an
increase in the prevalence of ESBL-producing isolates from 2.3% to
16.8%, with the least susceptibility to piperacillin and ampicillin
and 100% susceptibility to imipenem.21 Araj et al. found E. coli
susceptibility to imipenem to be 99.9% to 100% in their
2012 study.10 In the present study, the mean prevalence of
ESBL-producing E. coli isolates was 32.3%; quinolone resistance
was about 55% and imipenem resistance was 0.7%. As a result of
these ﬁndings, the empirical use of quinolones as ﬁrst-line therapy
in the treatment of urinary tract infections is now avoided. This
will be reﬂected in guidelines that are in preparation for
publication.
The prevalence of ESBL-producing Klebsiella pneumoniae iso-
lates was 20.0% in a study conducted in 2003 in a large hospital in
Beirut and 28% in a study performed at AUBMC in 2011.10,20 The
Table 6
Susceptibility rate of Acinetobacter spp and Pseudomonas spp obtained from 16 Lebanese hospitals.
Percentage susceptibility to the antimicrobial agents (number of isolates)
Acinetobacter spp Pseudomonas spp
2011 (242) 2012 (1704) 2013 (1463) p-Value All years
(3343)
2011 (1105) 2012 (3294) 2013 (3498) p-Value All years
(7897)
Pip–Taz 30.6 (242) 11.8 (1704) 11.1 (1397) <0.05a 12.9 80.5 (1105) 78.1 (3294) 80.7 (3498) <0.05b 79.6
Ceftazidime 24.7 (242) 11.6 (1704) 10.0 (1397) <0.05a 11.8 78.4 (1105) 81.4 (3294) 83.3 (3498) <0.05a 81.8
Cefepime 30.5 (242) 11.8 (1704) 12.5 (1463) <0.05a 13.4 78.7 (1105) 82.6 (3294) 84.3 (3498) <0.05a 82.8
Aztreonam 17.0 (219) 3.4 (1242) 9.0 (855) <0.05a,b 6.7 71.5 (1059) 76.2 (3173) 77.9 (3251) <0.05a 76.3
Imipenem 49.2 (242) 15.2 (1704) 15.1 (1463) <0.05a 17.6 79.6 (1105) 70.9 (3294) 72.5 (3498) <0.05a 72.8
Gentamicin 42.4 (242) 17.8 (1692) 15.5 (1450) <0.05a 18.6 81.9 (1105) 82.5 (3210) 82.7 (3407) 0.673 82.5
Amikacin 33.3 (228) 14.0 (1704) 15.4 (1397) <0.05a 15.9 89.2 (883) 87.1 (3294) 90.5 (3498) <0.05b 88.9
TMP–SMX 35.5 (228) 17.2 (1440) 15.3 (1231) <0.05a 17.8
Ciproﬂoxacin 24.0 (242) 10.6 (1704) 10.5 (1433) <0.05a 11.5 75.5 (1105) 74.8 (3294) 80.3 (3498) <0.05b 77.3
Colistin N/A 77.1 (552) 95.6 (254) <0.05b 82.9
Pip–Taz, piperacillin–tazobactam; TMP–SMX, trimethoprim–sulfamethoxazole.
p-Value reports signiﬁcant difference between any percentages.
a p-value <0.05 between 2011 and 2012.
b p-value <0.05 between 2012 and 2013.
Table 5
Susceptibility rate of Escherichia coli and Klebsiella spp obtained from 16 Lebanese hospitals
Percentage susceptibility to the antimicrobial agents (number of isolates)
Escherichia coli Klebsiella spp
2011 (4035) 2012 (12 003) 2013 (14 373) p-Value All years
(30 411)
2011 (963) 2012 (3222) 2013 (3698) p-Value All years
(7883)
Ampicillin 29.1 (1737) 23.6 (8704) 22.6 (12 544) <0.05a,b 23.1 0.0 (227) 0.0 (1973) 0.0 (2366) 0
Amox–Clav 66.7 (4035) 63.3 (12 003) 58.5 (14 373) <0.05a,b 61.4 71.1 (963) 68.2 (3222) 64.6 (3698) <0.05a,b 66.8
Pip–Taz 89.2 (3466) 86.8 (11 437) 78.9 (13 836) <0.05a,b 83.3 83.4 (872) 80.7 (3147) 79.5 (3599) <0.05a,b 80.5
Cefoxitin 82.7 (2306) 88.7 (10 917) 86.8 (10 635) <0.05a,b 87.3 81.0 (467) 88.0 (2754) 90.4 (2632) <0.05a,b 88.5
Cefuroxime 69.5 (3591) 62.0 (11 572) 57.3 (9499) <0.05a,b 59.2 71.4 (794) 63.1 (3074) 63.9 (2648) <0.05a 64.4
Cefotaxime 73.6 (1390) 66.1 (8569) 61.5 (10 100) <0.05a,b 64.3 75.9 (240) 65.0 (2113) 63.6 (2397) <0.05a,b 64.8
Ceftazidime 75.6 (3591) 70.5 (11 572) 69.1 (13 567) <0.05a,b 70.5 78.9 (794) 70.3 (3074) 68.7 (3467) <0.05a,b 70.5
Ceﬁxime 77.8 (821) 66.5 (5844) 68.7 (5798) <0.05a,b 68.3
Cefepime 85.2 (2278) 70.8 (11 006) 74.1 (13 030) <0.05a,b 73.7
Aztreonam 75.5 (2847) 63.3 (10 807) 66.7 (13 567) <0.05a,b 66.3 80.3 (679) 66.7 (2938) 68.3 (3403) <0.05a,b 68.8
Imipenem 99.5 (4035) 99.3 (12 003) 99.2 (14 373) 0.145 99.3 98.6 (963) 98.6 (3222) 97.3 (3698) <0.05b 98
Gentamicin 66.7 (4035) 72.7 (11 491) 72.2 (13 801) <0.05a,b 71.7 68.8 (963) 75.2 (3089) 75.6 (3549) <0.05a 74.6
Amikacin 96.7 (3291) 97.5 (12 003) 97.0 (14 373) <0.05a 97.2 94.2 (848) 96.7 (3222) 95.1 (3698) <0.05a,b 95.7
TMP–SMX 49.4 (4035) 48.0 (12 003) 49.8 (13 651) <0.05a,b 49 54.5 (963) 58.1 (3222) 55.8 (3524) <0.05a,b 56.6
Ciproﬂoxacin 57.4 (3035) 57.0 (12 003) 52.0 (14 373) <0.05b 54.7 72.2 (963) 71.8 (3222) 73.1 (3698) 0.372 72.5
Nitrofurantoin 95.4 (2306) 96.6 (7406) 95.6 (8710) <0.05a,b 96 61.6 (467) 54.1 (1789) 48.4 (2100) <0.05a,b 52.2
Tigecycline 100 (821) 97.3 (3795) 98.5 (5100) <0.05a,b 98.2 100 (149) 84.9 (883) 86.9 (1211) <0.05a,b 87
ESBL production rate 32 30.8 33.6 <0.05a,b 32.3 30.2 28.1 29.9 0.191 29.2
Amox–Clav, amoxicillin–clavulanic acid; Pip–Taz, piperacillin–tazobactam; TMP–SMX, trimethoprim–sulfamethoxazole; ESBL, extended-spectrum beta-lactamase.
p-Value reports signiﬁcant difference between any percentages.
a p-value <0.05 between 2011 and 2012.
b p-value <0.05 between 2012 and 2013.
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imipenem susceptibility of K. pneumoniae was 98%.
Concerning Acinetobacter, an 80% susceptibility rate to imipe-
nem was reported in 2010/11 from AUBMC.10The data of the present
study revealed a marked decrease in the rate of Acinetobacter
susceptibility to imipenem, from 49% in 2011 to 15% in 2013. Aci-
netobacter susceptibility to colistin was 83% in this study. A few
hospitals reported susceptibility to tigecycline, with a mean of
58.3%; only one hospital reported tigecycline susceptibility in
2011. There was an appreciable drop in tigecycline susceptibility
from 100% in 2011 to 39.6% in 2013. This could suggest outbreak
patterns in some of these hospitals; outbreaks can easily be caused
by this organism. In addition, these hospitals were probably
overusing tigecycline because of prior outbreaks. It is also important
to note that some hospitals only reported A. baumannii, so it is likely
that the mean value reported has shifted towards A. baumannii
susceptibilities. Previous studies investigating the basis of the
carbapenem resistance of multidrug-resistant A. baumannii havefound the resistance to be related to the production of carbapenem-
hydrolyzing oxacillinase OXA-58 encoded by a plasmid-borne
gene.22,23 Such data were not available from the hospitals in the
present study.
With regard to Pseudomonas species, high and variable
multidrug resistance rates have been reported.12 Mouawad et al.
showed a trend of increasing resistance of P. aeruginosa to all
antimicrobials in 2006 and 2009, with the highest resistance being
to ciproﬂoxacin (33%).24 In the present study, Pseudomonas
susceptibility to imipenem and ciproﬂoxacin was 73% and 77%,
respectively, less than the respective rates of 80% and 83% reported
previously.10,24 An increase in carbapenem resistance was noted in
the present study, while susceptibility to ceftazidime and
piperacillin–tazobactam was maintained at around 80% and to
aztreonam at around 75%. Of note, most hospitals reported P.
aeruginosa only, but others reported all Pseudomonas species.
Imipenem resistance was reported more in the Beirut area, which
could be a result of the increased use of carbapenems as a
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few years in Lebanon. In addition, ciproﬂoxacin resistance was
stable at around 23% during the study period.
There are some limitations to this study, mainly the biases
associated with patient presentation to healthcare (often patients
with prior treatment failure or complicated medical histories),
patient sampling practices, and test practices. The main, largest
hospitals reported the results by patient, avoiding duplicate isolates.
A few hospitals were unable to do this. However, the number of
isolates reported by these latter centres was low, with this limitation
outweighed by the beneﬁt of inclusion of the centres to provide a
nationwide perspective. A further limitation is that, while most
hospitals reported the bacterial susceptibility for inpatient and
outpatient cultures together, one hospital reported only suscepti-
bility for inpatient specimen cultures. Even for the hospitals
reporting cultures from outpatients, the data obtained did not
show prior recent admissions to the hospital or contact with recently
hospitalized patients. This is expected in a non-clinical study such as
the one presented here. This limitation is considered not to have
considerably affected the results, since a comparison of inpatients
and outpatients was not done. Another limitation is the different
antibiotic susceptibility methods used in the different hospitals
(Table 3). With regard to the use of European Committee for
Antimicrobial Susceptibility Testing (EUCAST) and CLSI guidelines
for the interpretation of resistance, EUCAST has published guidelines
for the performance and interpretation of antibiotic susceptibility
testing and has encouraged a change in the antibiotic susceptibility
testing systems to facilitate the comparison of results. The CLSI
updated its recommendations for the interpretation of in vitro drug
susceptibility testing results in their 2010 and 2011 guidelines,
based on clinical data, pharmacokinetic–pharmacodynamic prop-
erties, and minimal inhibitory concentration distributions, in part
adopting the EUCAST strategies.25 Since the present study period
extended from 2011 to 2013, the differences in interpretation
between the two recommendations were considered minimal; the
majority of Lebanese hospitals were using the CLSI guidelines.26,27 In
addition, it is important to note that the differences between the
EUCAST and CLSI systems after 2011 affect mostly intermediate
resistance rather than susceptibility or resistance. Finally, the mean
susceptibilities of all bacteria are presented in relation to the number
of isolates tested, as mentioned in all of the tables. However, most of
the standard antimicrobials used in determining the susceptibility
patterns were reported.
In spite of these limitations, the data reﬂect the national pattern
in an acceptable way. They are the only nationally compiled data
available to date and constitute a platform for the future.
It is concluded that antimicrobial resistance is becoming a
major problem in Lebanon. MRSA, penicillin- and erythromycin-
resistant S. pneumoniae, and differentially resistant Enterobacter-
iaceae, Pseudomonas, and Acinetobacter are all important threats
to the Lebanese population. A strategic plan is needed. The ﬁrst
step will be to establish a proper surveillance system after the
standardization of microbiological methods. This study provides
data that could assist clinicians in their daily practice and that may
help in establishing prevention and treatment guidelines. Finally
the results of this study could help direct further research efforts in
the future.
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